id,filing_uuid,filing_type,registrant_name,registrant_id,client_name,filing_year,filing_period,issue_code,specific_issues,government_entities,income_amount,expense_amount,is_no_activity,is_termination,received_date
1947947,3a5f3f0b-5635-436e-a648-cff95fb295bb,Q1,AMERICAN SOCIETY OF CONSULTANT PHARMACISTS,3446,AMERICAN SOCIETY OF CONSULTANT PHARMACISTS,2017,first_quarter,PHA,Pharmacy provider status,"Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",,40000,0,0,2017-03-24T14:26:46.610000-04:00
1948142,8c772158-223b-40bb-801b-ecac4510e90e,1T,QGA PUBLIC AFFAIRS (FORMERLY QUINN GILLESPIE & ASSOCIATES),54197,NEKTAR THERAPEUTICS,2017,first_quarter,PHA,FDA oversight of certain pain-reliever products,"HOUSE OF REPRESENTATIVES,SENATE",60000,,0,1,2017-04-01T13:25:56.923000-04:00
1948252,fd64d611-e2d9-4c18-8eaa-650a5d80dd79,Q1,AMERICAN AMBULANCE ASSOCIATION,56018,AMERICAN AMBULANCE ASSOCIATION,2017,first_quarter,PHA,Lobbied for passage of Protecting Patient Access to Emergency Medication Act (H.R. 304).,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",,280000,0,0,2017-04-03T08:16:32.013000-04:00
1948523,151a9b1a-0e47-415a-9866-36ca4445b2ef,Q1,KATE MOSS,25988,CVS HEALTH,2017,first_quarter,PHA,Legislation impacting PBMs and drug pricing,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2017-04-04T11:59:42.157000-04:00
1948600,3cbb2c51-8b95-4552-98aa-c628f477201d,Q1,AMERICAN COLLEGE OF CLINICAL PHARMACY,57258,AMERICAN COLLEGE OF CLINICAL PHARMACY,2017,first_quarter,PHA,Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs.,"Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",,128375,0,0,2017-04-04T14:35:58.480000-04:00
1948773,b38b497b-7287-45b6-bcb8-6eeb203d38a3,Q1,RED+BLUE STRATEGIES,400693064,EXPRESS SCRIPTS INC.,2017,first_quarter,PHA,"S. Con. Res. 3 - Budget Resolution for FY2017 - Impact of reconciliation instructions on the prescription drug benefit and coverage for those covered through health care market places and Medicaid beneficiaries. 

S. 637 - Creating Transparency to have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices.

S. 771 - A bill to Improve Access to Affordable Prescription Drugs - Issue related to bringing drug pricing down including better policies in the Part D coverage gap, couponing and advancing biosimilars.","Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2017-04-05T11:14:18.410000-04:00
1948852,24e25b3f-6938-4788-be6d-38a3df976712,Q1,RED+BLUE STRATEGIES,400693064,PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA),2017,first_quarter,PHA,"S. Con. Res. 3 - Budget Resolution for FY 2017 - Impact of reconciliation instructions on the prescription drug benefit and coverage for those covered through health care marketplaces and Medicaid beneficiaries. 

S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices. 

S. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars.","Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2017-04-05T14:34:39.670000-04:00
1948863,76f42342-654b-4454-a97d-bb971b0eeba0,Q1,RED+BLUE STRATEGIES,400693064,PEW CHARITABLE TRUSTS,2017,first_quarter,PHA,"Issues related to antibiotic innovation and advancement

Issues related opioid abuse and methods to fight against the opioid epidemic in the United States.

Issues related to ensuring the safety of compounded medications. 

Issues related to over the counter medications and supplements. 

Issues related to the Physician Payment Sunshine Act and the Open Payments system.","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2017-04-05T14:53:49.380000-04:00
1948873,c0d7ddce-5a0c-45a1-9725-04e6027dc510,Q1,AMERICAN CAPITOL GROUP,305852,CARDINAL HEALTH,2017,first_quarter,PHA,Issues Related to Distribution and Sale of Pharmaceutical and Medical Products and Services;,"HOUSE OF REPRESENTATIVES,SENATE",25000,,0,0,2017-04-05T15:09:55.747000-04:00
1949345,ad673291-e103-44f0-a9de-5dd10675ebd8,Q1,WAXMAN STRATEGIES,401103693,340B HEALTH,2017,first_quarter,PHA,Issues affecting the 340B drug pricing program,HOUSE OF REPRESENTATIVES,18750,,0,0,2017-04-07T14:48:44.613000-04:00
1950336,f757043d-43c2-4a6a-90e9-8822c87fd08c,Q1,HOLLAND & KNIGHT LLP,18466,PROTECTING ACCESS TO PAIN RELIEF COALITION,2017,first_quarter,PHA,Advocating for policy to ensure patient access to pain relief.,,50000,,0,0,2017-04-11T14:56:58.060000-04:00
1950342,045ae1f1-0879-4755-aa32-94e444ff899d,Q1,HOLLAND & KNIGHT LLP,18466,THE BIOSIMILARS FORUM,2017,first_quarter,PHA,"Medicare reimbursement issues, FDA regulation of biosimilars.","HOUSE OF REPRESENTATIVES,SENATE",120000,,0,0,2017-04-11T15:02:07.023000-04:00
1950374,331d86e1-153f-443d-ab2d-46c7df3068e6,Q1,"FLYNN & ASSOCIATES, INC.",15020,PHARMACEUTICAL INDUSTRY LABOR-MANAGEMENT ASSOCIATION,2017,first_quarter,PHA,"PDUFA Reauthorization
Importation of drugs from overseas","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2017-04-11T15:12:27.110000-04:00
1950440,e3407194-3390-4035-a76e-fe4fa0d902e3,Q1,"PARRY, ROMANI, DECONCINI & SYMMS",30792,ROCK & ASSOCIATES,2017,first_quarter,PHA,Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.,"HOUSE OF REPRESENTATIVES,SENATE",12000,,0,0,2017-04-11T15:52:17.723000-04:00
1951084,a6f118e1-e45a-472a-8c01-0a686f6a6674,Q1,KNIGHT CAPITOL CONSULTANTS,40036301,"EQUASHIELD, LLC",2017,first_quarter,PHA,Monitor issues related to Medical Device User Fee Act reauthorization (no bill yet),"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2017-04-12T14:28:26.520000-04:00
1951147,3d79f8a0-3285-4d2c-a149-0d7e2b0db7ec,1A,AMERICAN PHARMACISTS ASSOCIATION,3071,AMERICAN PHARMACISTS ASSOCIATION,2017,first_quarter,PHA,"HR 1038, S 413 Improving Transparency and Accuracy in Medicare Part D Spending Act
HR 1939 To amend title XVIII of the Social Security Act to ensure equal access of Medicare beneficiaries to community pharmacies in underserved areas as network pharmacies under Medicare prescription drug coverage, and for other purposes.
HR 592, S 109 To amend title XVIII of the Social Security Act to provide for coverage under the Medicare program of pharmacist services.
HR 1480 Safe and Affordable Drugs from Canada Act of 2017
S 637 Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
HR 1586 To amend the Federal Food, Drug, and Cosmetic Act to ensure that liquid over-the-counter medications are packaged with appropriate dosage delivery devices and, in the case of such medications labeled for pediatric use, appropriate flow restrictors, and for other purposes.
S 778 Prescription Drug Monitoring Act of 2017
HR 934 Personal Drug Importation Fairness Act of 2017
HR 421 Allowing Greater Access to Safe and Effective Contraception Act
HR 1436 To provide for reconciliation pursuant to title II of the concurrent resolution on the budget for fiscal year 2017.
HR 1245, S 469 To amend the Federal Food, Drug, and Cosmetic Act to allow for the importation of affordable and safe drugs by wholesale distributors, pharmacies, and individuals.","HOUSE OF REPRESENTATIVES,SENATE",,30000,0,0,2017-04-12T15:13:53.620000-04:00
1951148,48d8bbf6-fc2a-4612-83b6-89fa36ba3131,Q1,MR. VINCENT A. PANVINI,401008845,PHRMA,2017,first_quarter,PHA,Importation of Pharmaceuticals,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2017-04-12T15:15:54.700000-04:00
1951255,6eba9c9f-f1a5-4fd1-bfe8-398c75ec6806,Q1,INDEPENDENT PHARMACY COOPERATIVE,313098,INDEPENDENT PHARMACY COOPERATIVE,2017,first_quarter,PHA,"Support S. 109/H.R. 592, the Pharmacy and Medically Underserved Areas Enhancement Act
Support S.413/H.R. 1038, the ""Improving Transparency and Accuracy in Medicare Part D Drug Spending Act.
Ensure patient choice in Comprehensive Addiction and Recovery Act of 2016 lock-in provision.
Support Affordable Care Act of 2010 Average Manufacturer Price methodology.","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",,30000,0,0,2017-04-12T17:25:09.533000-04:00
1951324,2959c074-d9b5-497b-b6d4-0721014af51d,Q1,DAVE KOLBE CONSULTING,401104329,PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION,2017,first_quarter,PHA,"Medicare Part-D rebates
Trade agreements
Patent reform issues","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2017-04-12T20:56:23.747000-04:00
1951396,7b61d06e-57a6-4167-ab82-9ea7ec3d5f6c,Q1,MCDERMOTT+ LLC,401103287,ALLIANCE FOR RURAL HOSPITAL ACCESS,2017,first_quarter,PHA,Amendments to Section 340B of the Public Health Service Act to gain eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program.,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2017-04-13T09:40:44.973000-04:00
1952218,e63c7e03-0f7c-47dc-8688-49303a7e3e8c,Q1,PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION,31348,PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION,2017,first_quarter,PHA,"Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks.  

Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, Direct and Indirect Remuneration (DIR), pharmacy networks, and mail-service pharmacy.  

Issues related to the management of Medicaid prescription drug benefits. 

Issues related to prescription drug abuse.

Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price.  

HR.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act
H.R.1316, Prescription Drug Price Transparency Act
S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
S.771, Improving Access to Affordable Prescription Drug Act","Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),SENATE",693081,,0,0,2017-04-13T14:52:58.190000-04:00
1952237,361d12de-0b0e-4102-8c54-e120fbb2f86b,1A,PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION,31348,PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION,2017,first_quarter,PHA,"Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks.  

Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, Direct and Indirect Remuneration (DIR), pharmacy networks, and mail-service pharmacy.  

Issues related to the management of Medicaid prescription drug benefits. 

Issues related to prescription drug abuse.

Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price.  

HR.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act
H.R.1316, Prescription Drug Price Transparency Act
S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
S.771, Improving Access to Affordable Prescription Drug Act","Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),SENATE",,693081,0,0,2017-04-13T15:01:15.737000-04:00
1952608,dd12a8a9-560f-49f7-8d46-1dea22ada7f0,Q1,MR. GALEN RESER,401055978,PERRIGO INC (THROUGH FTI GOVERNMENT AFFAIRS),2017,first_quarter,PHA,"Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSAs and HSAs to purchase over-the-counter OTC medicines. FDA's proposed changes to generic drug labeling. House Energy and Commerce 21st Century Cures Initiative. Senate Health, Education, Labor and Pensions 21st Century Cures Initiative.","HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2017-04-13T18:51:00.003000-04:00
1952863,14ca0a61-8104-453a-8b0d-0f4694497b27,Q1,AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS,3457,AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS,2017,first_quarter,PHA,"Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Communication with FDA on Generic Drug User Fee Act, Prescription Drug user Fee Act, Biosimilar User Fee Act, and electronic drug information. Contact on manufacturing gaming REMS to gain market advantage","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE",,260000,0,0,2017-04-14T11:51:18.753000-04:00
1953307,8ca8e27c-24ac-4198-a085-8a70c6dddfc4,Q1,MR. BRIAN KELLY,40024191,LUNDBECK PHARMACEUTICALS,2017,first_quarter,PHA,"CNS
Brain Disorders
Alzheimer's","HOUSE OF REPRESENTATIVES,SENATE",15000,,0,0,2017-04-14T17:36:52.507000-04:00
1953326,abb6b468-42ec-4880-99e2-f9ce83da8072,Q1,THE D MAJOR GROUP,401103162,CVS CAREMARK,2017,first_quarter,PHA,Advocate for the protection of pharmaceutical benefit management and resulting cost savings.,"HOUSE OF REPRESENTATIVES,SENATE",34500,,0,0,2017-04-14T18:34:11.717000-04:00
1953521,271ca983-3e80-4ab3-9240-0b90dacfad1a,Q1,"POLITICAL CAPITAL, LLC",401104260,MEDISCA INC,2017,first_quarter,PHA,"DQSA
Oversight",Food & Drug Administration (FDA),15000,,0,0,2017-04-16T17:08:04.573000-04:00
1953530,734c605d-a7a9-4a99-892e-643ba9086316,Q1,APOTEX CORP.,310973,APOTEX CORP.,2017,first_quarter,PHA,"Federal policy relating to the reauthorization of the Generic Drug User Fee Act;

Federal policy relating to the cost of prescription pharmaceuticals;

Federal policy relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing, and for shared Risk Evaluation and Mitigation (REMS) programs for brand and generic pharmaceuticals;

HR 749, the Lower  Drug Costs Through Competition Act, provisions relating to priority review vouchers for and expedited approval of certain generic drug applications, and Risk Evaluation and Mitigation (REMS) programs; and

Draft legislation (no bill number) related to generic drug exclusivity and the review of Abbreviated New Drug Applications (ANDAs).","HOUSE OF REPRESENTATIVES,SENATE",,160000,0,0,2017-04-16T21:04:18.540000-04:00
1953557,b8d33cee-8c47-4ddf-932a-a95c6a016575,Q1,NATIONAL COMMUNITY PHARMACISTS ASSOCIATION,27478,NATIONAL COMMUNITY PHARMACISTS ASSOCIATION,2017,first_quarter,PHA,"Congressional Oversight of 340 B Program;
Issues related to FDA implementation of The Drug Quality and Security Act related to the regulations of pharmacy compounding;
Biosimilar naming;
H.R. 421 Allowing Greater Access to Safe and Effective Contraception Act","Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),Office of Natl Drug Control Policy (NDCP),Office of Personnel Management (OPM),SENATE,White House Office",,370000,0,0,2017-04-17T08:10:36.257000-04:00
1953667,2cd6cbc2-8c9a-4f96-86ec-af6925c50817,Q1,ROCK & ASSOCIATES,33545,"BRAIDWOOD MANAGEMENT, INC.",2017,first_quarter,PHA,Issues pertaining to pharmacy compounding.,"HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2017-04-17T09:24:19.837000-04:00
1953675,47553295-eaf6-46ed-b294-68539bce3e68,Q1,ROCK & ASSOCIATES,33545,DIAMONDBACK DRUGS,2017,first_quarter,PHA,Legislation pertaining to pharmacy compounding.,"HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2017-04-17T09:27:26.073000-04:00
1953685,f8e490b8-fda8-43e7-8504-44b39576b42c,Q1,ROCK & ASSOCIATES,33545,"VETERINARY PHARMACIES OF AMERICA, INC.",2017,first_quarter,PHA,Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.,"HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2017-04-17T09:28:31.417000-04:00
1953691,46926c7a-0072-4872-a1b5-9e857830b0ac,Q1,ROCK & ASSOCIATES,33545,"WEDGEWOOD VILLAGE PHARMACY, INC.",2017,first_quarter,PHA,Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.,"HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2017-04-17T09:29:36.747000-04:00
1953698,c735433b-6eb2-4c0a-acb4-907c7c496031,Q1,ROCK & ASSOCIATES,33545,WOMEN'S INTERNATIONAL PHARMACY,2017,first_quarter,PHA,Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.,"HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2017-04-17T09:31:43.450000-04:00
1953701,b1c16673-0995-478c-81f8-ce717dcf2d25,Q1,ROCK & ASSOCIATES,33545,WELLNESS PHARMACY,2017,first_quarter,PHA,Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.,"HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2017-04-17T09:31:44.557000-04:00
1954373,62c12396-9bf4-4542-bfc7-dd52ead0e0be,Q1,NELSON MULLINS RILEY & SCARBOROUGH,285871,CASCADE HEMOPHILIA CONSORTIUM,2017,first_quarter,PHA,Issues related to 340B Drug Pricing Program,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2017-04-17T14:31:54.937000-04:00
1954386,41a088e8-5f3d-4db9-982d-2001ab16feaf,Q1,NELSON MULLINS RILEY & SCARBOROUGH,285871,HEMOPHILIA OF GEORGIA,2017,first_quarter,PHA,Issues related to the 340B Drug Pricing Program and the proposed American Health Care Act,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2017-04-17T14:34:01.767000-04:00
1954409,78848480-fcbd-4ad1-ba62-74ce476e955b,Q1,RED+BLUE STRATEGIES,400693064,BLUE CROSS BLUE SHIELD OF MASSACHUSETTS,2017,first_quarter,PHA,Issues related to curbing the abuse of opioids in the United States.,"HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2017-04-17T14:39:22.313000-04:00
1954492,36235c2e-6b77-425e-8624-9ab1abeaf601,Q1,RED+BLUE STRATEGIES,400693064,COHERUS BIOSCIENCES,2017,first_quarter,PHA,"S. 771 - A bill to improve access to affordable prescription drugs - issues related to ensuring a healthy market for biosimilar medications. 

Issues related to the upcoming biosimilars User Fee Agreement legislation. 

Issues related to the treatment of biosimilar medications in Medicare Part B and D programs. 

Issues related to the maintenance of current IPR laws.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2017-04-17T15:01:23.567000-04:00
1954512,5f9132a5-dbd2-4e34-9f54-6f7add896501,Q1,"MERCURY PUBLIC AFFAIRS, LLC",70175,KALISPELL REGIONAL HEALTHCARE,2017,first_quarter,PHA,Veteran pharmacy issues and polices,"Federal Communications Commission (FCC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA)",30000,,0,0,2017-04-17T15:06:39.097000-04:00
1954618,2ac27f6b-9216-469f-a84c-c5d47fcae34a,Q1,DENTONS US LLP,36105,PHRMA,2017,first_quarter,PHA,Any federal issues regarding the research and development of pharmaceuticals,,,,0,0,2017-04-17T15:28:40.757000-04:00
1955107,a6b71256-4916-4bd9-abd0-f2b4bd32850e,Q1,BROYDRICK & ASSOCIATES,7268,TONIX PHARMACEUTICALS,2017,first_quarter,PHA,Funding for a new drug for PTSD.,"Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2017-04-17T20:13:18.170000-04:00
1955249,1b5f222e-b07d-4acd-88e9-3ccdac3035a6,Q1,THORN RUN PARTNERS,400534596,"EXPRESS SCRIPTS, INC.",2017,first_quarter,PHA,"Pharmacy benefits manager standards under the Medicare prescription drug program to further transparency of payment methodologies to pharmacies. Issues related to a pilot program in TRICARE that would establish Department of Defense (DoD) acquisition cost parity for prescription drugs obtained at community pharmacies. Drug reimbursement and general pharmacy related issues. S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017; issues related to transparency of pharmacy benefit managers (PBMs).","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2017-04-17T23:43:39.820000-04:00
1955475,5b6d2656-c707-422f-9ddf-ac74a62bf754,Q1,MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE),400265214,MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE),2017,first_quarter,PHA,"Pricing, shortages, and safety issues","Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",,250000,0,0,2017-04-18T09:43:29.367000-04:00
1955517,beea3ce5-3441-4c8d-a1cc-9d48e0d2d639,1A,MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE),400265214,MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE),2017,first_quarter,PHA,"Pricing, shortages, and safety issues","Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",,139625,0,0,2017-04-18T09:55:00.087000-04:00
1955711,ed1a1120-d948-404e-90f8-f0aca18a48d7,Q1,ANIMAL HEALTH INSTITUTE,4037,ANIMAL HEALTH INSTITUTE,2017,first_quarter,PHA,Issues related to illegal drug manufacturing under the guise of pharmacy compounding; Issues related to the granting of Categorical Exclusions for animal health products.,"HOUSE OF REPRESENTATIVES,SENATE",,35000,0,0,2017-04-18T10:51:41.640000-04:00
1955785,c640a20c-2fd3-4ca6-841d-755e77b682e2,Q1,RAMPY NORTHRUP LLC,401103289,ACADEMY OF MANAGED CARE PHARMACY,2017,first_quarter,PHA,"Dissemination of pharmacoeconomic information. 
Implementation of 21st Century Cures Act (P.L.114-255).","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2017-04-18T11:12:39.503000-04:00
1956048,71171336-c561-44dc-9342-7f71fd0b4836,Q1,BLUECROSS BLUESHIELD OF TENNESSEE,6440,BLUECROSS BLUESHIELD OF TENNESSEE,2017,first_quarter,PHA,Precision Medicine Act; General Pharmacy Issues; Opioid Abuse; specialty drug pricing,"Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,30000,0,0,2017-04-18T12:11:56.280000-04:00
1956167,8989da2f-fcf2-438f-82b7-1ea493abcba4,Q1,THE INGRAM GROUP LLC,400577737,ELI LILLY AND COMPANY,2017,first_quarter,PHA,General issues related to the biopharmaceutical and pharmaceutical industries including drug importation.,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2017-04-18T12:35:17.753000-04:00
1956338,032a4cdd-cf0c-4478-ac62-85288a5bf24a,Q1,HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA),28776,HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA),2017,first_quarter,PHA,"Rx Pedigree (Public Law 113-54); Ensuring Patient Access and Effective Enforcement Act (Public Law 114-145); Prescription Drug Abuse - General issues related to Rx drug abuse; Importation of Prescription Drugs (S 469, S 771, HR 1776, HR 1245, HR 934, HR 1480, S 92, S 64), Implementation of Public Law 113-54 (DSCSA)","Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,313000,0,0,2017-04-18T13:14:05.053000-04:00
1956553,83b0ebb5-072b-446e-b802-9c26bc25f735,Q1,MASSACHUSETTS MEDICAL SOCIETY,23975,MASSACHUSETTS MEDICAL SOCIETY,2017,first_quarter,PHA,"S. 771 - Improving Access to Affordable Prescription Drugs - Legislation that seeks to address prescription drug costs by increasing transparency and accountability, boosting access and affordability of key drugs, spurring innovation, and increasing choice and competition by allowing Medicare to negotiate the price of drugs, among other provisions.","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",,100000,0,0,2017-04-18T13:54:05.730000-04:00
1956602,c17e2590-ab69-4e35-a676-8827d118cdd6,Q1,ASCENSION HEALTH,53301,ASCENSION HEALTH,2017,first_quarter,PHA,"Drug pricing; Creating and Restoring Equal Access to Equivalent Samples Act of 2016 (CREATES)
FAIR Drug Pricing Act","Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,290000,0,0,2017-04-18T14:05:43.043000-04:00
1956950,807ff530-02b3-4010-9c22-0d89c6d61d6a,Q1,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,AMERICAN SOCIETY OF HEMATOLOGY,2017,first_quarter,PHA,"HR 1409, Cancer Drug Coverage Parity Act","Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",30000,,0,0,2017-04-18T15:08:28.067000-04:00
1956973,8d9dbba7-d018-472d-bff1-8e54332d02d2,Q1,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,THE HEMOPHILIA ALLIANCE,2017,first_quarter,PHA,Issues related to the 340B drug discount program,"Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2017-04-18T15:11:43.677000-04:00
1957010,a13e8a00-2924-49df-afd2-e589373cb016,Q1,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,NATIONAL HEMOPHILIA FOUNDATION,2017,first_quarter,PHA,"Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing programs.","Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",50000,,0,0,2017-04-18T15:17:10.600000-04:00
1957029,261b521b-05c5-4c21-9511-f88e948eb20a,Q1,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,NATIONAL ASSOCIATION OF EPILEPSY CENTERS,2017,first_quarter,PHA,Issues related to anti-epileptic drugs.,"Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",10000,,0,0,2017-04-18T15:20:23.850000-04:00
1957104,59ae3162-7ba9-4104-8528-451cdbb1fb73,Q1,FTI GOVERNMENT AFFAIRS,401054971,"PERRIGO, INC.",2017,first_quarter,PHA,"Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines. FDA's proposed changes to generic drug labeling. House Energy and Commerce 21st Century Cures Initiative. Senate Health, Education, Labor and Pensions 21st Century Cures Initiative.","HOUSE OF REPRESENTATIVES,SENATE",150000,,0,0,2017-04-18T15:31:13.587000-04:00
1957209,4486f685-3894-41bf-b39d-0fd88f8a78b8,Q1,THE MATHIS HARPLE GROUP,322911,PILMA,2017,first_quarter,PHA,Importation of Pharmaceuticals,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2017-04-18T15:45:11.010000-04:00
1957291,30d251c2-4172-465d-9bb4-70472e247152,Q1,ACADEMY OF MANAGED CARE PHARMACY,48793,ACADEMY OF MANAGED CARE PHARMACY,2017,first_quarter,PHA,Supporting the dissemination of pharmacoeconomic information and urging Congress to continue its efforts against allowing substandard and dangerous counterfeit drugs to be imported across U.S. borders,"Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)",,119000,0,0,2017-04-18T15:53:59.167000-04:00
1957341,e61cb369-47dc-4018-bc2a-bef975fb0779,Q1,FTI GOVERNMENT AFFAIRS,401054971,PROFESSIONAL COMPOUNDING CENTERS OF AMERICA,2017,first_quarter,PHA,"Implementation of The Drug Quality and Security Act, H.R.3204 (Public Law) ((USP/NF Monograph)).","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2017-04-18T16:01:24.730000-04:00
1957369,53915d13-a552-480a-a65b-4d0c2acf7c62,Q1,NOVO NORDISK INC.,284790,NOVO NORDISK INC.,2017,first_quarter,PHA,Issues related to Prescription Drug User Fee Act VI; issues related to 340B program; H.R. 1245/S. 469 Affordable and Safe Prescription Drug Importation Act,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE",,1270000,0,0,2017-04-18T16:09:40.510000-04:00
1957383,be8aa1b6-6a96-426b-8b6f-a2702e66492e,Q1,"EVERGREEN ASSOCIATES, LTD.",13984,PHARMACEUTICAL PRINTED LITERATURE ASSOCIATION,2017,first_quarter,PHA,"- Docket ID: FDA-2007-N-0363: Electronic Distribution of Content of Labeling for Human Prescription Drug and Biological Product
- Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017, Prescription Drug labeling 
- Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018, Prescription Drug labeling
- FDA User Fees reauthorization (no bill)
- Patient Medication Information","HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2017-04-18T16:11:50.683000-04:00
1957745,ced4b287-ffa2-4512-991e-61b4e21a6ff3,Q1,"TARPLIN, DOWNS & YOUNG, LLC",304736,HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.),2017,first_quarter,PHA,"Importation of prescription drugs (S. 469)
Rx Pedigree (PL 113-54)
Prescription Drug Monitoring Programs (S. 480, H.R. 1725)
Prescription Drug Abuse - General issues related to Rx drug abuse 
Ensuring Patient Access and Effective Enforcement Act (PL 114-145)","Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2017-04-18T17:36:35.023000-04:00
1957758,ea3587aa-674c-4281-9cf3-ca45a0a64d9f,Q1,TRAVERE THERAPEUTICS,401104190,TRAVERE THERAPEUTICS,2017,first_quarter,PHA,"Orphan Drug Act, Drug Quality and Security Act, drug pricing, Prescription Drug User Fee Act reauthorization, FDA issues","HOUSE OF REPRESENTATIVES,SENATE",,140000,0,0,2017-04-18T17:38:39.677000-04:00
1958010,43a811ee-0c0f-4659-89fa-605ef9da4d91,Q1,ISEMAN & ASSOCIATES LLC,401103582,"TICHENOR VENTURES, LLC",2017,first_quarter,PHA,Monitoring biotech legislation,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2017-04-18T21:19:02.907000-04:00
1958073,acbfda6a-8f5c-461c-85ab-30761e39bac1,Q1,WEST FRONT STRATEGIES LLC,401103493,WALGREEN CO.,2017,first_quarter,PHA,"Pharmacy and Medically Underserved Areas Enhancement Act (S. 109 and HR 592), to amend Title IIX of the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved areas.","HOUSE OF REPRESENTATIVES,SENATE,White House Office",60000,,0,0,2017-04-18T22:05:50.100000-04:00
1958625,cb181d1b-0944-429c-b2d9-cac70a09cfa5,Q1,"TARPLIN, DOWNS & YOUNG, LLC",304736,ASTRAZENECA,2017,first_quarter,PHA,"PL 112-144 - The Food and Drug Administration Safety and Innovation Act, implementation
PL 114-255 - 21st Century Cures, implementation

***, no specific bill(s), Import Safety, drug development policy, drug shortages, supply chain integrity, patent settlements, user fee reauthorization, Innovation","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2017-04-19T09:34:12.040000-04:00
1958739,27ccdcf7-aab4-4b78-aa1c-e0a8c1a6c202,Q1,"TARPLIN, DOWNS & YOUNG, LLC",304736,PHRMA,2017,first_quarter,PHA,"PL 114-255 - 21st Century Cures, implementation
H.R. 1628 - American Health Care Act of 2017

***, no specific bill(s), prescription drug importation, import safety, supply chain integrity, Prescription Drug User Fee Act Fee Reauthorization and associated policies, user fee sequester, innovation","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2017-04-19T09:54:33.997000-04:00
1958885,08cff4a1-14ac-4c5e-af16-e708cf7bb240,Q1,SC PARTNERS LLC,318994,"PFIZER, INC.",2017,first_quarter,PHA,"Advocated for maintaining a safe prescription drug supply, and shared concerns about the safety and economic implications of allowing the importation of prescription drugs and biologics from Canada and other countries. 

Affordable and Safe Prescription Drug Importation Act (S. 469)","HOUSE OF REPRESENTATIVES,SENATE",6000,,0,0,2017-04-19T10:14:49.063000-04:00
1959162,a60d6279-1a18-4cb2-abbc-567c0181a2dc,Q1,CHAMBER HILL STRATEGIES,400645947,AMAG PHARMACEUTICALS (FORMERLY KNOWN AS LUMARA PHARMACEUTICAL),2017,first_quarter,PHA,"Implementation issues related to P.L. 113-54, the Drug Quality and Security Act.","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2017-04-19T10:46:46.533000-04:00
1960406,0d00913e-87bf-4557-a2e2-b0009f6fae22,Q1,UNIVERSITY OF IOWA,49191,UNIVERSITY OF IOWA,2017,first_quarter,PHA,"FY 17 and FY 18 appropriations for NIH
Support for palliative care programs","Administration for Children & Families (ACF),Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Education, Dept of,Energy, Dept of,Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,State, Dept of (DOS),Transportation, Dept of (DOT)",,86662,0,0,2017-04-19T13:22:00.943000-04:00
1960656,ff1c2a20-2bf5-4648-96b0-0373601b3ec1,Q1,"POWERS PYLES SUTTER & VERVILLE, P.C.",32008,340B HEALTH,2017,first_quarter,PHA,"Section 340B of the Public Health Services Act, Section 1927 of the Social Security Act and issues related to (1) administration and Congressional oversight of the 340B Drug Discount Program, (2) implementation of 340B-related provisions in the Patient Protection and Affordable Care Act of 2010, and (3)finding of the Health Resources and Services Administration (HRSA) under the Labor Health & Human Services & education appropriations bills.","HOUSE OF REPRESENTATIVES,SENATE",15000,,0,0,2017-04-19T13:50:47.743000-04:00
1960756,4711e8f6-fbf3-4a82-ac94-57ca337c7053,Q1,LEHIGH VALLEY HEALTH NETWORK,40041332,LEHIGH VALLEY HEALTH NETWORK,2017,first_quarter,PHA,S.109 The Pharmacy and Medically Under-served Areas Enhancement Act,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2017-04-19T13:59:45.387000-04:00
1960760,42b8faaf-f373-4540-b783-daeadc1fdba1,Q1,"ALKERMES, INC.",400458235,"ALKERMES, INC.",2017,first_quarter,PHA,"Public law #114-198, Cures Opioid Funding Implementation 
Reauthorization of the Prescription Drug User Fee Act (PDUFA)","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA),Veterans Affairs, Dept of (VA)",,920000,0,0,2017-04-19T14:00:47.760000-04:00
1960787,46d3f622-d8f8-4f39-af56-5e32a3d1b7b8,Q1,NATIONAL HOME INFUSION ASSOCIATION,40047365,NATIONAL HOME INFUSION ASSOCIATION,2017,first_quarter,PHA,"Compounding pharmacy regulation - worked to ensure DQSA (Pub L. 113-54) is being properly implemented, specifically the draft memorandum of understanding for 503 A pharmacies and FDA inspections of 503A pharmacies.
Lobbied for the inclusion of Department of Agriculture/FDA appropriations language regarding inspection authority and scope of the draft memorandum of understanding
Lobbied on proper inspections of 503A pharmacies","Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,170000,0,0,2017-04-19T14:01:58.213000-04:00
1960994,083f6602-cfe4-4f38-968e-899932dd0c2b,Q1,ELI LILLY AND COMPANY,13392,ELI LILLY AND COMPANY,2017,first_quarter,PHA,Hospital discounts; 340B program,"Agriculture, Dept of (USDA),Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR)",,1390000,0,0,2017-04-19T14:16:42.823000-04:00
1961277,fbecfe50-1b45-49e4-9e1f-c5e79c3f8eae,Q1,AMERICAN VETERINARY MEDICAL ASSOCIATION,3630,AMERICAN VETERINARY MEDICAL ASSOCIATION,2017,first_quarter,PHA,"Discussions with Congressional staff and FDA to express the need for compounding of medications for use in animals and FDA's draft GFI #230
Discussions with DEA regarding use of controlled substances by veterinary practitioners, transportation of controlled substances, telemedicine and prescription monitoring programs.
Discussions with Congressional staff about mandatory prescription writing for veterinarians.
H.R. 623 Fairness to Pet Owners Act
Veterinary Compounding Draft Legislation","Agriculture, Dept of (USDA),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE",,220000,0,0,2017-04-19T14:36:59.093000-04:00
1961288,9d16e355-16d6-4ce3-94fd-eb837c7f7b4b,Q1,"ALLERGAN USA, INC.",63837,"ALLERGAN USA, INC.",2017,first_quarter,PHA,"Ensuring the safety of the drug supply chain to protect patients and keep Americans safe.
Drug Compounding.
Drug Importation/Counterfeit Drugs.","Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Patent & Trademark Office (PTO),SENATE",,1200000,0,0,2017-04-19T14:38:04.060000-04:00
1961313,aea2a516-ca1a-4c0a-a063-921090ddb41d,Q1,"MEHLMAN CONSULTING, INC.",284950,FOOD ALLERGY RESEARCH & EDUCATION (FARE),2017,first_quarter,PHA,Issues related to drug pricing.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2017-04-19T14:39:16.517000-04:00
1961413,ae5f1c96-4644-42b3-b647-5a6b4458bfbc,Q1,"TARPLIN, DOWNS & YOUNG, LLC",304736,BIOTECHNOLOGY INDUSTRY ORGANIZATION,2017,first_quarter,PHA,"PL 114-255 - 21st Century Cures, implementation

***, no specific bill(s), Drug Safety, Prescription Drug Importation, Import Safety, supply chain integrity, biosimilars, PDUFA and associated policies, patent settlements, accelerated approval, break through therapies, compounding, user fee reauthorization, Innovation","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE",80000,,0,0,2017-04-19T14:50:16.327000-04:00
1961689,14fa4fba-0444-4fa1-875a-8ced07b6d1bd,Q1,BUCHANAN INGERSOLL & ROONEY PC,55291,BRECKENRIDGE PHARMACEUTICAL INC,2017,first_quarter,PHA,FDA related Application issues; pricing of prescription drugs,"Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2017-04-19T15:22:20.460000-04:00
1961914,f42d4c19-d27e-4a5b-9992-5045ae6fe709,1T,BUCHANAN INGERSOLL & ROONEY PC,55291,"PHARMACEUTICAL ASSOCIATES, INC.",2017,first_quarter,PHA,Strategy development and implementation of company's federal government relations initiatives. FDA process of enforcement of manufactured drugs.,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,1,2017-04-19T15:38:39.947000-04:00
1961963,b74cb7fd-987b-4365-ae8a-c54a7cd61f25,Q1,HANCE SCARBOROUGH,17443,ALLIANCE FOR PHARMACY COMPOUNDING,2017,first_quarter,PHA,Issues related to the regulation of pharmacy compounding.,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2017-04-19T15:42:06.633000-04:00
1962007,2be50893-2226-47dc-9e98-646456cd567d,Q1,BUCHANAN INGERSOLL & ROONEY PC,55291,TONIX PHARMACEUTICALS HOLDING CORP.,2017,first_quarter,PHA,Federal funding related to clinical trials for military PTSD,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2017-04-19T15:46:34.180000-04:00
1962032,d69465ca-a5e3-4365-8bf3-951480ad9988,Q1,"ASSOCIATION OF NATIONAL ADVERTISERS, INC.",4653,"ASSOCIATION OF NATIONAL ADVERTISERS, INC.",2017,first_quarter,PHA,Proposals relating to the regulation of direct-to-consumer prescription drug advertising,"Federal Communications Commission (FCC),HOUSE OF REPRESENTATIVES,SENATE",,430000,0,0,2017-04-19T15:46:40.603000-04:00
1962136,bd6d055d-8b1a-40a6-8073-aad16b355e2b,Q1,AKIN GUMP STRAUSS HAUER & FELD,682,"PHARMEDIUM SERVICES, LLC",2017,first_quarter,PHA,"Drug Quality and Security Act, Pub. L. 113-54; FDA regulatory implementation of Section 503B of the Food, Drug and Cosmetic Act; FDA Pharmacy Compounding Advisory Committee; House & Senate Agriculture, FDA & Related Agency Appropriations bills.","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2017-04-19T15:52:37.917000-04:00
1962243,5adb61f6-a43d-420c-889e-f902bc9f79cf,Q1,KING & SPALDING LLP,21632,"SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.)",2017,first_quarter,PHA,Issues related to inclusion of prescription drugs within Essential Health Benefit and mental health coverage expansion,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2017-04-19T15:59:42.447000-04:00
1962613,479c09d5-1517-40e5-beea-f41f4f6f03be,Q1,PRIME THERAPEUTICS,400339576,PRIME THERAPEUTICS,2017,first_quarter,PHA,Generic drug user fee act - provisions to ensure greater market competition for generics. Biosimilar drug user fee act - ensuring greater competition in the biosimilar market. S.469/H.R.1245: Affordable and Safe Prescription Drug Importation Act. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act - issues relating to ensuring a competitive drug marketplace. S.778:Prescription Drug Monitoring Act - issues related to dispensers access to PDMPs across state lines.,"HOUSE OF REPRESENTATIVES,SENATE",,40000,0,0,2017-04-19T16:28:39.407000-04:00
1962728,9057e537-5ee4-481c-ae4c-040b80a3084d,Q1,NATIONAL ASSOCIATION FOR THE ADVANCEMENT OF COLORED PEOPLE,48975,NATIONAL ASSOCIATION FOR THE ADVANCEMENT OF COLORED PEOPLE,2017,first_quarter,PHA,"Support maintaining ACA Patient Protections and Access to Prescription drugs
Support S. 469 / HR 1245, the Affordable and Safe Prescription Drug Importation Act 
Support Klobuchar Amendment #178 to S. Con. 3 which established a deficit neutral fund relating to lower drug prices for Americans by importing prescription drugs from Canada.
Support Wyden amendment #188 to S Con Res 3 creating a point of order against legislation that does not lower drug prices.","Agriculture, Dept of (USDA),Bureau of Alcohol Tobacco Firearms & Explosives,Centers For Medicare and Medicaid Services (CMS),Consumer Financial Protection Bureau (CFPB),Education, Dept of,Election Assistance Commission (EAC),Environmental Protection Agency (EPA),Federal Communications Commission (FCC),Federal Motor Carrier Safety Administration,Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Housing & Urban Development, Dept of (HUD),Justice, Dept of (DOJ),Labor, Dept of (DOL),Natl Park Service (NPS),Office of Management & Budget (OMB),Office of the Comptroller of the Currency (OCC),Securities & Exchange Commission (SEC),SENATE,Social Security Administration (SSA),Transportation, Dept of (DOT),Treasury, Dept of,White House Office",,68750,0,0,2017-04-19T16:35:23.750000-04:00
1962786,9ffa2307-156d-4e6e-beff-88a9843e587e,Q1,CONSUMER HEALTHCARE PRODUCTS ASSOCIATION,29403,CONSUMER HEALTHCARE PRODUCTS ASSOCIATION,2017,first_quarter,PHA,"Pseudoephedrine

Potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient, common in popular cold and allergy medications (no bill number) and oppose prescription requirement (no bill number).

Oral Contraceptives

H.R. 421/S. 93 - Allowing Greater Access to Safe and Effective Contraception Act of 2017. Grants priority review of applications to switch oral contraceptive drugs from prescription to nonprescription (over-the-counter) status; all sections.

Over-the-counter (OTC) medicines; Manufacturing and importation of OTC drugs; Mandatory recall authority of the FDA; Rx-to-OTC Switch

Supporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines.","Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of",,252000,0,0,2017-04-19T16:40:55.500000-04:00
1962824,1cbf1771-5091-4d75-aeb8-1644e19fa54c,Q1,COVINGTON & BURLING LLP,11195,CELGENE CORPORATION,2017,first_quarter,PHA,"Expressing support for changes to the CREATES Act (S. 3056), Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051), Lower Drug Costs through Competition Act (H.R. 749) and Senate counterpart (S. 297, Increasing Competition in Pharmaceuticals Act), and Affordable and Safe Prescription Drug Importation Act (S. 469).","HOUSE OF REPRESENTATIVES,SENATE",70000,,0,0,2017-04-19T16:43:14.797000-04:00
1962982,ce8bb03a-a0bc-484a-ac81-498d36492ae2,Q1,"AMERICAN FEDERATION OF STATE, COUNTY AND MUNICIPAL EMPLOYEES",2321,AMERICAN FEDERATION OF STATE COUNTY AND MUNICIPAL EMPLOYEES,2017,first_quarter,PHA,"HR 1628- American Health Care Act of 2017
S 771, HR 1776- Improving Access to Affordable Prescription Drugs Act","HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE,White House Office",,630000,0,0,2017-04-19T16:52:32.533000-04:00
1963011,93ac099b-4eb2-4a7f-b813-cc6335ee74dc,Q1,RUBIN AND RUDMAN LLP,400942719,BLINK HEALTH LTD (A BERMUDA LIMITED COMPANY),2017,first_quarter,PHA,"Advocate for client before members of the U.S. House of Representatives, U.S. Senate, and staffs to each, with respect to market based solutions to drug pricing and chain pharmacy barriers to generic pharmaceutical price reduction.","HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2017-04-19T16:53:43.797000-04:00
1963411,95b5ffaf-6148-4b6c-9b67-6ee08ba629e1,1A,NOVO NORDISK INC.,284790,NOVO NORDISK INC.,2017,first_quarter,PHA,Issues related to Prescription Drug User Fee Act VI; issues related to 340B program; H.R. 1245/S. 469 Affordable and Safe Prescription Drug Importation Act,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE",,1270000,0,0,2017-04-19T17:32:04-04:00
1963547,ae777d99-f805-4c5c-9470-9a8b1403aa68,Q1,"HIGHMARK, INC.",18238,HIGHMARK INC,2017,first_quarter,PHA,"Opioid Epidemic, Rx costs, transparency, formulary limitations","HOUSE OF REPRESENTATIVES,SENATE",,350000,0,0,2017-04-19T17:49:45.977000-04:00
1963597,03592d9a-b10f-4634-aefc-e368b36cc7bf,Q1,"ML STRATEGIES, LLC",25603,THE CAMPAIGN FOR SUSTAINABLE RX PRICING,2017,first_quarter,PHA,Issues related to prescription drug pricing; S. 3056 - CREATES Act,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2017-04-19T17:55:17.070000-04:00
1963778,0545a2c3-9954-4ba7-a628-f1d9d03adf18,Q1,THORSEN FRENCH ADVOCACY LLC,400599826,"CARDINAL HEALTH, INC.",2017,first_quarter,PHA,"Issues related to prescription drug abuse.
Issues related to pharmaceutical market value.","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2017-04-19T18:30:58.077000-04:00
1963787,b97a2a34-4a0c-449e-8151-3e4d64908676,Q1,NATIONAL NURSES UNITED,40021153,NATIONAL NURSES UNITED,2017,first_quarter,PHA,"S.469 - Affordable and Safe Prescription Drug Importation Act, to allow prescription drug importation","HOUSE OF REPRESENTATIVES,Occupational Safety & Health Administration (OSHA),SENATE",,50000,0,0,2017-04-19T18:34:07.170000-04:00
1963829,cddbe6ae-2979-484e-b6a8-a004ec0fa3dc,Q1,THORSEN FRENCH ADVOCACY LLC,400599826,HEALTHCARE DISTRIBUTION ALLIANCE,2017,first_quarter,PHA,"General issues related to prescription drug abuse.
Issues related to pharmaceutical market value. 
Prescription drug importation.","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2017-04-19T18:42:37.560000-04:00
1963915,5a9949cf-63cf-4937-abbf-ca634139ce8b,Q1,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN),2017,first_quarter,PHA,"Policy matters related to generic pharmaceuticals and biosimilars, including reauthorization of the Generic Drug User Fee Agreement, reauthorization of the Biosimilar User Fee Agreement, H.R. 2051, The FAST Generic Act of 2017, S.771/H.R. 1776, Improving Access to Affordable Drugs, and changes to the Risk Evaluation and Mitigation Strategies (REMS) program.  Issues related to drug takeback and opioid addition.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2017-04-19T19:08:54.357000-04:00